Reuters logo
U.S. FDA panel backs approval of Novo Nordisk diabetes drug
2017年10月18日 / 晚上8点35分 / 1 个月前

U.S. FDA panel backs approval of Novo Nordisk diabetes drug

WASHINGTON, Oct 18 (Reuters) - Novo Nordisk A/S’s new diabetes drug semaglutide is effective, reasonably safe and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.

The panel voted 16-0 with one abstention in favor of the drug being approved. It would compete with others in a class known as glucagon-like peptide-1 (GLP-1) analogs, which imitate an intestinal hormone that stimulates the production of insulin.

The FDA typically follows the recommendations of its advisors. (Reporting by Toni Clarke; Editing by Sandra Maler)

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below